Study Type
|
Title of Study
|
| RHEUMATOID ARTHRITIS |
| Treatment/Interventional |
TARGET: To compare the effects on vascular inflammation of TNFi + MTX versus triple therapy in subjects with RA who are inadequate responders to MTX using FDG PET/CT as a tool for detecting vascular (arterial) inflammation.
|
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact Jeraldine 310-206-4007
|
| Observational |
Longitudinal Cardiovascular Risk Study of Patients with Rheumatoid Arthritis
|
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact Jeraldine 310-206-4007
|
| Treatment |
StopRA: Study to determine if hydroxychloroquine is safe and effective for the prevention of future onset of RA in people with elevated anti-CCP levels.
|
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461
|
| Treatment |
CANNABIS: Cannabis Anonymous Questionnaire in UCLA Rheumatology Patients. |
Principal Investigators
Veena K. Ranganath, MD, MS, RhMSUS
For more information, contact Nicolette Morris 310-825-9956
|
| Treatment |
ACTHAR: Use of ACTHAR in Rheumatoid Arthritis Related Flares. |
Principal Investigators
Veena K. Ranganath, MD, MS, RhMSUS
For more information, contact Nicolette Morris 310-825-9956
|
|
UPCOMING STUDIES
|
| Treatment |
CANNABIDIOL: Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
|
Principal Investigators
Veena K. Ranganath, MD, MS, RhMSUS
For more information, contact Nicolette Morris 310-825-9956
|
| SYSTEMIC LUPUS ERYTHEMATOSIS |
| Observational |
Precise: Looking for inpatient active lupus patients upon initial admission (prior to steroids) to follow longitudinally for disease activity. |
Principal Investigators
Jennifer King, MD, PhD
For more information contact Samya 310-825-2548 |
| Treatment |
ALE09: Study to evaluate the efficacy, safety, and tolerability of lenabasum (synthetic cannabinoid) in decreasing pain associated with arthritis or tendonitis in lupus patients. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
| Treatment |
Eli Lilly JAHZ: Study to determine the effect of baricitinib and standard-of-care therapy on lupus disease activity. |
Principal Investigators
Jennifer Grossman, MD
For more information contact Julia 310-825-6461 |
| Observational |
Pro-inflammatory HDL Cholesterol: Evaluating biomarkers of risk for atherosclerosis in lupus. Involves a one-time blood draw. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Lucas 310-825-2598 |
| Treatment |
IDEAL: Evaluating the value of educational information about the risks and benefits of lupus medications. Implementation of the DEcision-Aid for Lupus in practice settings for shared decision-making. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
| Treatment |
BMS PAISLEY: A study to evaluate the efficacy and safety of BMS-986165 in improving renal function in lupus nephritis patients who do not adequately respond to mycophenolate mofetil (MMF). |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
|
UPCOMING STUDIES
|
| Observational |
GSK Belimumab in Early Lupus: A study to evaluate the effects of belimumab in patients recently diagnosed with lupus. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
| Treatment |
Amgen AMG570: A study evaluating the safety and efficacy AMG 570 in lupus patients. |
Principal Investigators
Maureen McMahon, MD, MS
For more information contact Julia 310-825-6461 |
| SCLERODERMA |
| Treatment |
BRAVOS ITN075AI: Study of an Investigational Drug, Brentuximab Vedotin, for Diffuse Cutaneous Systemic Sclerosis |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
Cumberland: A Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Systemic Sclerosis Systemic Sclerosis-Associated Pulmonary Arterial Hypertension |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
CORBUS JBT101-SSc-002: A study to evaluate efficacy and safety of Lenabasum in diffuse cutaneous Systemic Sclerosis |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Observational (Long-Term Follow-Up) |
ASSET Long Term Follow-Up: A long term follow-up on ASSET: A study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Observational |
GRASP: Genome Research in African American Scleroderma Patients (GRASP) |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Observational |
SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) cohort collecting data on a regular basis related to problems likely to be important for many people living with scleroderma |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Observational |
PI-Initiated: A study to define the differences in IMMUNE RESPONSES in skin from patients with an autoimmune or inflammatory condition |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
SLS III: A combination study of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related lung disease |
Co-Principal Investigator
Elizabeth Volkmann, MD, MS
Co-Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
SLS III: Mycophenolate vs. Mycophenolate + Pirfenidone for SSc-ILD |
Co-Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact Paul Lopez or Eileen Callahan 310-794-2466
|
| Treatment |
Forbius: A novel TGF-beta inhibitor for patients with diffuse cutaneous sclerosis |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-990-3520
|
| Treatment |
CSL Behring: IVIG for patients with diffuse cutaneous sclerosis |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-990-3520
|
| Observational |
SSc Microbiome study: Any patient with systemic sclerosis |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-990-3520
|
| Observational |
The Gut Microbiome as a Screening Tool for ILD in SSc |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-990-3520
|
| Observational |
Biomarkers to Predict Treatment Response in SSc-ILD |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-990-3520
|
| Observational |
CURESSC - Consortium of Universities to REsearch Scleroderma in Southern California |
Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-990-3520
|
| Observational |
Scleroderma Clinical Trial Consortium: The gastrointestinal Microbiome as a Marker of disease Activity in Systemic Sclerosis |
Co-Principal Investigator
Elizabeth Volkmann, MD, MS
For more information, contact 310-990-3520
|
| Treatment |
Galapagos GLPG1690: A study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 (ATX inhibitor) |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| UPCOMING STUDIES |
| Treatment |
Kadmon KD025-209: A study to evaluate the efficacy and safety of KD025 (ROCK2 inhibitor) in subjects with diffuse cutaneous Systemic Sclerosis |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
Eicos ES-301: A study evaluating the safety and efficacy of IV Iloprost in subjects with systemic sclerosis experiencing symptomatic digital ischemic episodes |
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| Treatment |
IgPro10_2001: Study to evaluate the efficacy and safety of IgPro10 (intravenous immunoglobulin, Privigen®) for the treatment of adults with Systemic Sclerosis
|
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
PSORIATIC ARTHRITIS & ANKYLOSING SPONDYLITIS
|
| Treatment |
Novartis CAIN457F2354: A study to assess the time course of response to secukinumab on joint inflammation using Power Doppler ultrasonography in patients with active psoriatic arthritis
|
Principal Investigator
Suzanne Kafaja, MD
For more information, contact Isabel 310-825-9682
|
| MYOSITIS |
| Observational |
Longitudinal Cohort Study of Patients with Idiopathic Inflammatory Myopathies
|
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact Jeraldine 310-206-4007
|
| Treatment |
Corbus: Lenabasum for patients with active dermatomyositis
|
Principal Investigators
Elizabeth Volkmann, MD, MS
For more information contact Paul Lopez or Eileen Callahan 310-794-2466
|
|
UPCOMING STUDIES
|
| Treatment/Interventional |
CSL Behring: A study to evaluate the efficacy safety, and pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) in adults with dermatomyositis (DM)
|
Principal Investigators
Christina Charles-Schoeman, MD, MS
For more information contact Jeraldine 310-206-4007
|
| SJOGREN'S SYNDROME |
| Observational |
NGS Sjogren’s: Looking for primary Sjogren’s patients, both seropositive SSA+ or seronegative; especially with parotid swelling
|
Principal Investigator
Jennifer King, MD
For more information, contact Samya 310-825-2548
|
| VASCULITIS |
|
No Studies at this time |
|
| GOUT |
|
No Studies at this time |
|
| UPCOMING STUDIES |
|
No Studies at this time |
|
| CONNECTIVE TISSUE DISEASE-INTERSTITIAL LUNG DISEASE (CTD-ILD) |
| Observational |
CTD-ILD Registry: Any patient with a CTD-ILD |
Principal Investigators
Elizabeth Volkmann, MD, MS
For more information contact Paul Lopez or Eileen Callahan 310-794-2466 |
